最新ニュース Biogen (NASDAQ:BIIB) 株価情報

BIOGEN INC

Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biotech

Earnings

News

Guidance

Health Care

Movers

General

BIIB

米国バイオテクノロジー大手（BIIB）バイオジェン（Biogen Inc）が、2022年第2四半期の調整後1株当たり利益（EPS）を前年同期比31％増の5.28ドル（約607円）と発表し、コンセンサス予想の4.03ドルを上回ったと見られている。

米テクノロジー大手　バイオジェン　コンセンサス予想上回る

Biogen Inc

<a href="https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease">https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease</a>.

ACIU

ANVS

DNLI

PRTA

RHHBF

RHHBY

SAVA

'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA

Despite a powerful 22% surge in the S&amp;P 500 since the April lows—driven by easing U.S.-China trade tensions and a 90-day pause on new tariffs—only half of the index&#8217;s stocks have managed to rise above their 200-day moving average, indicating a market rally <a href="https://www.benzinga.com/movers">that remains potentially incomplete.</a>
This technical indicator, often used to gauge long-term trends and market breadth, currently shows that just 49.9% of S&amp;P 500 components are in what traders would consider a bullish trend. 
That figure remains below both the five- and 10-year averages of 60%, suggesting a wide swath of the market has yet to participate in the rebound.
<h3 class="wp-block-heading">Breadth Gauge Shows Room To Run</h3>
Over the past four years, the percentage of stocks above their 200-day moving average has moved within a wide 10% to 92% range. The extreme lows—seen in June and September 2022 at just 10%—came during periods of heightened recession fears and monetary tightening. 
The recent cycle bottom occurred just last month, when the figure dipped to 15% following April's sharp, tariff-driven selloff.
The highest reading in the last four years came in May 2021, at 92%, during a time of peak post-pandemic optimism. More recently, a high of 82% was recorded in September 2024, following the start of Federal Reserve policy easing. 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-1024x529.png" alt="" class="wp-image-914932" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-1536x793.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-2048x1058.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">What Analysts Say About The Tariff Pause and Market Reaction</h3>
Analysts say that the 90-day tariff truce announced in April and this week&#8217;s truce between the U.S. and China helped revive risk appetite, but they remain cautious about its long-term effects.
In a note on Wednesday, Peter Oppenheimer, strategist at Goldman Sachs, said the outcome was "much better than we had expected," noting that the tariff levies of 30 percentage points by the U.S. and +5 points by China were significantly lower than prior worst-case estimates.
Oppenheimer also highlighted that the new U.S.-UK trade agreement contributes to a more constructive global growth outlook and has mitigated fears of long-term economic damage from the April drawdown.
He added that the market has begun to price out recession risks. 
"Certainly, recent news has been supportive for risk in three respects: it has shown the U.S. Administration to be pragmatic and keen to de-escalate&#8230; it suggests a lower likely outcome for the average effective tariff rate&#8230; and it has led to a number of growth upgrades," he said.
Rick Gardner, chief investment officer at RGA Investments, said markets are already "pricing in an environment where the U.S. and China are able to trade with each other," even if some economic weakness persists.
"Even if we see a continued economic slowdown, the stock market may have already priced that in during the April selloff," Gardner said.
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 20 Laggards – Price vs. 200-Day Moving Average</h3>
More than 20 S&amp;P 500 stocks are still trading over 20% below their 200-day moving averages, highlighting substantial technical room for recovery among the index's biggest underperformers during the tariff-relief rally. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Below 200-Day Moving Average</th>
</tr>
</thead>
<tbody>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-42.20%</td>
</tr>
<tr>
<td>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>-41.52%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-30.14%</td>
</tr>
<tr>
<td>Alexandria Real Estate Equities Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>)</td>
<td>-29.88%</td>
</tr>
<tr>
<td>Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</td>
<td>-28.40%</td>
</tr>
<tr>
<td>Albemarle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>-27.11%</td>
</tr>
<tr>
<td>IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>)</td>
<td>-26.14%</td>
</tr>
<tr>
<td>Bio-Techne Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>)</td>
<td>-24.95%</td>
</tr>
<tr>
<td>Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)</td>
<td>-24.89%</td>
</tr>
<tr>
<td>LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>)</td>
<td>-24.88%</td>
</tr>
<tr>
<td>Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>)</td>
<td>-24.48%</td>
</tr>
<tr>
<td>Teradyne Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>)</td>
<td>-24.35%</td>
</tr>
<tr>
<td>West Pharmaceutical Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>)</td>
<td>-24.06%</td>
</tr>
<tr>
<td>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)</td>
<td>-23.67%</td>
</tr>
<tr>
<td>Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-23.18%</td>
</tr>
<tr>
<td>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>-23.06%</td>
</tr>
<tr>
<td>Becton, Dickinson and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>-22.80%</td>
</tr>
<tr>
<td>Halliburton Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>)</td>
<td>-22.30%</td>
</tr>
<tr>
<td>Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>)</td>
<td>-21.76%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data as of May 13, 2025</figcaption></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45399438/smci-rated-outperform-by-raymond-james-amid-dominance-in-branded-ai-server-market">SMCI Stock In &#8216;Sweet Spot,&#8217; Says Raymond James — Sets $41 Price Target As AI Revenue Hits 70%</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Equities

Large Cap

Economics

Analyst Ratings

ENPH

REGN

TECH

Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and lowers the price target from $207 to $169.

Price Target

Mizuho Maintains Outperform on Biogen, Lowers Price Target to $169

JP Morgan analyst Chris Schott maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Neutral and lowers the price target from $185 to $175.

JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $175

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and lowers the price target from $217 to $205.

RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $205

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $265 to $220.

Canaccord Genuity Maintains Buy on Biogen, Lowers Price Target to $220

HC Wainwright &amp; Co. analyst Andrew Fein maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $241 to $187.

HC Wainwright & Co. Maintains Buy on Biogen, Lowers Price Target to $187

Baird analyst Brian Skorney maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and lowers the price target from $300 to $255.

Baird Maintains Outperform on Biogen, Lowers Price Target to $255

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Biogento Hold

Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That&#8217;s down from $3.67 a year ago, beating <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the analyst consensus of $2.52</a>.
The company <a href="https://investors.biogen.com/static-files/cbd0307c-c394-4d4a-a388-c7511bbacb8f" target="_blank" rel="noreferrer noopener">reported</a> sales of $2.43 billion, up 6% year over year on a reported basis, 8% on constant currency, beating the consensus of $2.23 billion.
Multiple sclerosis revenue of $953 million decreased by 11% (down 10% on constant currency). The multiple sclerosis drug Tysabri sales were down to $381.5 million&nbsp;<a href="https://www.benzinga.com/general/biotech/25/02/43635908/what-to-expect-from-alzheimers-drugmaker-biogens-q4-earnings-on-wednesday" target="_blank" rel="noreferrer noopener">from $431.3 million</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44652995/vertex-alnylam-best-positioned-as-biopharma-braces-for-tariff-impact-goldman-sachs-analyst-flags-regeneron-biogen-risks" rel="noreferrer noopener">Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks</a>
Rare disease revenue&nbsp;increased&nbsp;33% year over year (up 36% on constant currency) to $563 million. Spinraza&#8217;s revenue increased to $423.9 million from $341.3 million a year ago.
Revenues from Skyclarys, acquired via Reata acquisition, reached $123.9 million during the quarter, up from $78 million a year ago.
U.S. Skyclarys revenue of approximately $69 million was impacted by expected Medicare discount dynamics partially offset by demand growth.
In Alzheimer&#8217;s disease, Biogen said Leqembi&#8217;s first quarter global in-market sales of approximately $96 million, including U.S. in-market sales of approximately $52 million, representing continued sequential growth.
Guidance:&nbsp;Biogen lowers full year 2025 adjusted <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43659412/biogen-warns-lower-2025-revenue-inks-rd-funding-pact-with-royalty-pharma-for-late-stage-lupus-asset" rel="noreferrer noopener">EPS outlook from $15.25-$16.25</a>&nbsp;to $14.50-$15.50 versus a consensus of $4.92.
The guidance reflects the ~($0.95) impact from a $165 million upfront transaction payment to Stoke related to the collaboration agreement for zorevunersen in Dravet syndrome, partially offset by a $0.20 benefit mainly from foreign exchange.
For 2025, Biogen expects total revenue to decline by a mid-single-digit percentage. Further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.
Potential tariffs are not expected to significantly affect the company&#8217;s 2025 financial outlook, even if the current exemption for pharmaceuticals ends:
Many of its products sold in the U.S. are made domestically
It has strong global inventory levels. However, Biogen notes that the future of U.S. and international tariffs is still unclear, and its forecast does not account for any new tariffs that might be introduced.
In April, the European Commission approved&nbsp;Eisai Co., Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALY#OTC">ESALY</a>) and&nbsp;Biogen&#8217;s amyloid-beta (Aβ) monoclonal&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44846884/europe-approves-eisai-biogens-alzheimers-drug-under-strict-conditions-after-initial-negative-opinion" rel="noreferrer noopener">antibody Leqembi&nbsp;(lecanemab)</a>. The Commission said it&nbsp;<a target="_blank" href="https://ec.europa.eu/newsroom/sante/items/879055/en?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">granted</a>&nbsp;the approval under strict conditions.
Price Action:&nbsp;BIIB stock is up 0.80% at $122.05 at $130&nbsp;at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/05/45139492/kellanova-misses-q1-revenue-and-earnings-estimates-due-to-weak-global-demand-and-currency-pressure" target="_blank" rel="noreferrer noopener">Kellanova Misses Q1 Revenue And Earnings Estimates Due To Weak Global Demand And Currency Pressure</a></li>
</ul>
Image: Shutterstock

ESALY

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact

Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) lowers FY2025 Adj EPS guidance from $15.25-$16.25 to $14.50-$15.50 vs $14.92 analyst estimate..

Biogen Lowers FY2025 Adj EPS Guidance from $15.25-$16.25 to $14.50-$15.50 vs $14.92 Est

Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported quarterly earnings of $3.02 per share which beat the analyst consensus estimate of $2.52 by 19.84 percent. This is a 17.71 percent decrease over earnings of $3.67 per share from the same period last year. The company reported quarterly sales of $2.43 billion which beat the analyst consensus estimate of $2.23 billion by 8.85 percent. This is a 6.11 percent increase over sales of $2.29 billion the same period last year.

Earnings Beats

Biogen Q1 Adj. EPS $3.02 Beats $2.52 Estimate, Sales $2.43B Beat $2.23B Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

Truist Securities analyst Srikripa Devarakonda maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $210 to $199.

Truist Securities Maintains Buy on Biogen, Lowers Price Target to $199

Piper Sandler analyst Christopher Raymond maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Neutral and lowers the price target from $135 to $115.

Piper Sandler Maintains Neutral on Biogen, Lowers Price Target to $115

Goldman Sachs analyst Salveen Richter maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $219 to $197.

Goldman Sachs Maintains Buy on Biogen, Lowers Price Target to $197

14 analysts have shared their evaluations of Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $190.21, with a high estimate of $265.00 and a low estimate of $135.00. Highlighting a 9.82% decrease, the current average has fallen from the previous average price target of $210.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359228_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Biogen is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $225.00&#x7C;$221.00 &#x7C; 
&#x7C;Matthew Harrison &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $152.00&#x7C;$157.00 &#x7C; 
&#x7C;Christopher Raymond &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $135.00&#x7C;$138.00 &#x7C; 
&#x7C;George Farmer &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Outperform&#x7C; $224.00&#x7C;$244.00 &#x7C; 
&#x7C;Evan Seigerman &#x7C;BMO Capital &#x7C;Lowers &#x7C;Market Perform &#x7C; $139.00&#x7C;$156.00 &#x7C; 
&#x7C;Matthew Harrison &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $157.00&#x7C;$192.00 &#x7C; 
&#x7C;Salveen Richter &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $245.00&#x7C;$281.00 &#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $225.00&#x7C;$231.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $145.00&#x7C;$160.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $140.00&#x7C;$165.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Buy &#x7C; $241.00&#x7C;$300.00 &#x7C; 
&#x7C;Srikripa Devarakonda&#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $210.00&#x7C;$220.00 &#x7C; 
&#x7C;Sumant Kulkarni &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $265.00&#x7C;$298.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $160.00&#x7C;$190.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Biogen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Biogen's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Biogen analyst ratings.</a>
<h2>Get to Know Biogen Better</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>A Deep Dive into Biogen's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Biogen's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.87%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Biogen's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 10.86%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Biogen's ROE stands out, surpassing industry averages. With an impressive ROE of 1.61%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.95%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.4.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

14 Analysts Have This To Say About Biogen

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and raises the price target from $221 to $225.

RBC Capital Maintains Outperform on Biogen, Raises Price Target to $225

US President Donald Trump issued a multi-part executive order on Tuesday to lower drug prices and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">reduce Medicare costs</a>.
Within 60 days, the Secretary of Health and Human Services is instructed to seek guidance for the Medicare Drug Price Negotiation Program for initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028.
<ul>
<li>This guidance will focus on greater transparency, selecting high-cost drugs, and safeguarding pharmaceutical innovation.</li>
<li>Additionally, the administration seeks to eliminate a key disparity in how Medicare treats small-molecule drugs compared to biologics, discouraging investment in more affordable treatments.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
The White House is also <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/" rel="noreferrer noopener">targeting</a> the rising costs seniors face under Medicare. A new payment model will be tested within a year to obtain better value for high-cost drugs and biologicals, including those not subject to price negotiations.
Further, the administration wants to align Medicare payments with actual hospital acquisition costs through a national survey, with potential reimbursement adjustments following the results.
To reform Medicaid drug pricing, the administration will develop recommendations linking drug payments to their value and ensuring accurate rebate payments from manufacturers. The initiative also aims to assist states in managing spending while promoting innovation in Medicaid reimbursement.
Affordability for life-saving medications is another key focus: Community health centers will be required to offer insulin and epinephrine at or below discounted 340B prices to low-income individuals with high out-of-pocket costs or no insurance, with compliance tied to eligibility for future federal grants..
To address price manipulation in the supply chain, the administration calls for reevaluating middlemen roles, such as pharmacy benefit managers, and seeking transparency in their compensation structures. Within 90 days, recommendations to promote a more efficient pharmaceutical market are expected.
Other planned reforms include accelerating FDA approvals for generics and over-the-counter conversions, streamlining the drug importation program, and ensuring Medicare payments do not incentivize hospital-based care over less costly physician offices.
Lastly, federal agencies will investigate anti-competitive practices by drug manufacturers, with public listening sessions and policy recommendations expected within six months.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44826592/netflix-wants-to-be-the-next-1-trillion-company-analyst-highlights-growth-path" target="_blank" rel="noreferrer noopener">Netflix Wants To Be The Next $1 Trillion Company, Analyst Highlights Growth Path</a></li>
</ul>
Photo by Aria Armoko via Shutterstock

Government

Regulations

ABBV

GILD

VRTX

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction

Press Releases

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

APLS

STOK

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Mizuho

JP Morgan

RBC Capital

Canaccord Genuity

HC Wainwright & Co.

Screenshot 2025-03-12 at 4.47.01 PM

ELDN

TNXP

Tonix&#39;s TNX-1500 Shows Promise In Preventing Organ Transplant Rejections Of Either Human Or Pig Organs; Autoimmune Diseases Also A Target

米国バイオテクノロジー大手<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">（BIIB）</a>バイオジェン（Biogen Inc）が、2022年第2四半期の調整後1株当たり利益（EPS）を前年同期比31％増の5.28ドル（約607円）と発表し、<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noopener">コンセンサス予想の4.03ドルを上回った</a>と見られている。
同社はまた、その四半期の売上高が24億7000万ドル（前年同期と同水準で、実質通貨ベースでは1％増）を<a href="https://investors.biogen.com/news-releases/news-release-details/biogen-reports-second-quarter-2024-results" target="_blank" rel="noopener">発表</a>し、こちらもまたコンセンサス予想の23億8000万ドルを上回った。
多発性硬化症（MS）の売上高は11億5000万ドル（実質通貨ベースでは5％減）で、MS治療薬タイサブリ（Tysabri）の売上高は、4億6220万ドル（前年同期は4億8310万ドル）に減少した。
また読む： <a href="https://www.benzinga.com/general/biotech/24/07/39935226/sage-biogen-shelve-development-of-nervous-system-disorder-drug-after-data-disappoints" target="_blank" rel="noopener">Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints</a>（英）
希少疾患分野の売上高は、前年同期比22％増（実質通貨ベース25％増）の5億3400万ドルに増加した。
スピンラーザ（Spinraza）の売上高は1億4291万ドル（前年同期は1億4371万ドル）に減少した。
Reata社の買収を通じて取得したスカイクラリス（Skyclarys）からの収益はこの四半期1億ドルに達した。小児用適応の投与量探索試験が進行中だ。
アルツハイマー病治療薬のレケンビ（Leqembi）発売では、第2四半期のグローバル市場内売上高が約4000万ドル（米国内の市場売上高は約3000万ドルを含む）となる加速した順次成長が実現した。
産後うつ病治療薬ザルズヴェ（Zurzuvae）の第2四半期の売上高は1億5000万ドルだ。
今後の見通し： 2024会計年度について、バイオジェンは2024年の調整後1株当たり利益（EBITDA）の予想を前回の15億ドルから15.75億ドルから16.25億ドル<a href="https://www.benzinga.com/general/biotech/24/04/38410191/biogens-leqembi-commercial-ramp-up-modest-but-up-ticking-reports-mixed-bag-q1-earnings" target="_blank" rel="noopener">へ引き上げた</a>。コンセンサス予想は15.58億ドルだ。
バイオジェンはまた、2024年の売上高の減少率については低単桁（先に見込んでいた低～中単桁より）としており、2024年のコア医薬品売上高については、新製品の売上高の増加により、MS製品の売上高のさらなる減少が相殺される見込み。
2024年について2023年と比較して、バイオジェンはオペレーティング収益が中単桁から10％を超える割合で増加し、オペレーティング利益率も中単桁から1桁の割合で改善すると予想している。
株価情報： 本日（木曜日）最終取引時点でBIIB株は1.96％下落の209.03ドルとなっている。
次の一手
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39985709/biogeneisais-alzheimers-drug-leqembi-gets-no-go-from-european-drug-regulators-advisory-panel-cite" target="_blank" rel="noopener">バイオジェン/アイカイサイ（Eisai）のアルツハイマー病治療薬レケンビ（Leqembi）、欧州の医薬品規制当局諮問委員会から「No Go」と判断される</a>（英）</li>
</ul>

Comments

Biogen

ニュース

最新ニュース Biogen (NASDAQ:BIIB) 株価情報

木曜日, 8 01, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル